Sort   by:  
 Page size 
ProteomicsDIPG harbour alterations targetable by MEK inhibitors, with acquired resistance mechanisms overcome by combinatorial inhibition
The survival of children with DIPG remains dismal, with new treatments desperately needed. In the era of precision medicine, targeted therapies represent an exciting treatment opportunity, yet resistance can rapidly emerge, playing an important role in treatment failure. In a prospective biopsy-stra...
ORGANISM(S): Homo sapiens (Human) 
2021-07-20 | PXD019701 | Pride
Lc-msms Tmt Clinical Dipg 
ProteomicsMulti-omics identify LRRC15 as a COVID-19 severity predictor and persistent pro-thrombotic signals in convalescence
We performed longitudinal blood sampling of end-stage kidney disease (ESKD) patients with COVID-19, collecting samples pre-infection and serially during infection. SomaLogic proteomics data were generated for two cohorts. The Wave 1 cohort consists of samples collected from ESKD patients during the ...
ORGANISM(S): Homo sapiens (Human) 
2025-03-17 | PAD000003 | Pride
Affinity proteomics Somascan 
UnknownPrevention of persistent pain with lidocaine infusions in breast cancer surgery (PLAN): study protocol for a multicenter randomized controlled trial.
Not available
S-EPMC11110187 | biostudies-literature
UnknownDocetaxel for Nonmetastatic Prostate Cancer: Long-Term Survival Outcomes in the STAMPEDE Randomized Controlled Trial.
Not available
S-EPMC9338456 | biostudies-literature
UnknownAddition of docetaxel to hormonal therapy in low- and high-burden metastatic hormone sensitive prostate cancer: long-term survival results from the STAMPEDE trial.
Not available
S-EPMC6938598 | biostudies-literature
UnknownAdding abiraterone or docetaxel to long-term hormone therapy for prostate cancer: directly randomised data from the STAMPEDE multi-arm, multi-stage platform protocol.
Not available
S-EPMC5961425 | biostudies-literature
UnknownAbiraterone acetate plus prednisolone for metastatic patients starting hormone therapy: 5-year follow-up results from the STAMPEDE randomised trial (NCT00268476).
Not available
S-EPMC9321995 | biostudies-literature
UnknownQuality of Life in Men With Prostate Cancer Randomly Allocated to Receive Docetaxel or Abiraterone in the STAMPEDE Trial.
Not available
S-EPMC7612717 | biostudies-literature
UnknownDiabetic macular oedema and diode subthreshold micropulse laser (DIAMONDS): study protocol for a randomised controlled trial.
Not available
S-EPMC6373040 | biostudies-literature
UnknownAbiraterone for Prostate Cancer Not Previously Treated with Hormone Therapy.
Not available
S-EPMC5533216 | biostudies-literature
Sort   by:  
 Page size